Daniel Seth Fierer

Daniel Seth Fierer

Auto-generated profile, based on publicly available information

Daniel Seth Fierer

Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai , New York, New York

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
FAFatima Amanat
Fatima Amanat
DSDaniel Stadlbauer
Daniel Stadlbauer
SSShirin Strohmeier
Shirin Strohmeier
TNThi Hoang Oanh Nguyen
Thi Hoang Oanh Nguyen
VCVeronika Chromikova
Veronika Chromikova
Florian KrammerFlorian Krammer
Florian Krammer

2 December 2017 in Hepatology
Verified
Journal Article
Open access
PDF file
DLDarrick K. Li
Darrick K. Li
YRYanjie Ren
Yanjie Ren
DFDaniel S. Fierer
Daniel S. Fierer
SRStephanie Rutledge
Stephanie Rutledge
OSObaid S. Shaikh
Obaid S. Shaikh
ABAdeel A. Butt
Adeel A. Butt
Recent studies have reported higher rates of hepatocellular carcinoma (HCC) in individuals treated with direct‐acting antivirals (DAAs). However, making definitive conclusions has been challenging because of the heterogeneous populations and methodologies of these reports. We investigated whether DAA use is associated with higher rates of incident HCC compared to treatment with interferon (IFN)‐based regimens. We performed a retrospective, population‐based cohort study using the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) database. In a cohort of 17,836 persons, sustained virological response (SVR) was achieved by 66.6% and 96.2% of the IFN and DAA groups, respectively. Among all treated persons, risk of HCC was not higher in the DAA group compared to the IFN group (hazard ratio, 1.07; 95% confidence interval, 0.55, 2.08). Among persons with cirrhosis who achieved SVR, neither the HCC incidence rate nor HCC‐free survival were significantly different in the DAA group compared to the IFN group (21.2 vs. 22.8 per 1,000 person‐years; P = 0.78 and log‐rank P = 0.17, respectively). Untreated persons with cirrhosis had a significantly higher HCC incidence rate (45.3 per 1,000 person‐years) compared to those treated with either IFN or DAAs (P = 0.03). Both groups of treated persons had significantly lower probability of HCC development compared to untreated persons (log‐rank, P = 0.0004). Conclusion: DAA treatment is not associated with a higher risk of HCC in persons with cirrhosis with chronic HCV infection in the short term. Previously reported higher rates of HCC associated with DAA treatment may be explained by both the presence of relatively fewer baseline HCC risk factors in persons treated with IFN as well as selection bias, given that DAA regimens were used to treat persons at higher risk for developing HCC. (Hepatology 2018;67:2244‐2253).

1 June 2014 in Journal of Virology
Verified
Journal Article
Open access
PDF file
RARaymond A. Alvarez
Raymond A. Alvarez
RHRebecca E. Hamlin
Rebecca E. Hamlin
AMAnthony Monroe
Anthony Monroe
BMBrian Moldt
Brian Moldt
MHMathew T. Hotta
Mathew T. Hotta
BCBenjamin Chen
Benjamin Chen
The type I interferon-inducible factor tetherin retains virus particles on the surfaces of cells infected withvpu-deficient human immunodeficiency virus type 1 (HIV-1). While this mechanism inhibits cell-free viral spread, the immunological implications of tethered virus have not been investigated. We found that surface tetherin expression increased the antibody opsonization ofvpu-deficient HIV-infected cells. The absence of Vpu also stimulated NK cell-activating FcγRIIIa signaling and enhanced NK cell degranulation and NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). The deletion ofvpuin HIV-1-infected primary CD4+T cells enhanced the levels of antibody binding and Fc receptor signaling mediated by HIV-positive-patient-derived antibodies. The magnitudes of antibody binding and Fc signaling were both highly correlated to the levels of tetherin on the surfaces of infected primary CD4 T cells. The affinity of antibody binding to FcγRIIIa was also found to be critical in mediating efficient Fc activation. These studies implicate Vpu antagonism of tetherin as an ADCC evasion mechanism that prevents antibody-mediated clearance of virally infected cells.IMPORTANCEThe ability of the HIV-1 accessory factor to antagonize tetherin has been considered to primarily function by limiting the spread of virus by preventing the release of cell-free virus. This study supports the hypothesis that a major function of Vpu is to decrease the recognition of infected cells by anti-HIV antibodies at the cell surface, thereby reducing recognition by antibody-dependent clearance by natural killer cells.

1 September 2008 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
DFDaniel S. Fierer
Daniel S. Fierer
AUAlison J. Uriel
Alison J. Uriel
DCDamaris C. Carriero
Damaris C. Carriero
AKArielle Klepper
Arielle Klepper
DDDouglas T. Dieterich
Douglas T. Dieterich
ABAndrea D. Branch
Andrea D. Branch
Outbreaks of acute hepatitis C virus (HCV) infection are occurring in HIV-infected men who have sex with men. We evaluated risk factors and liver his

20 September 2000 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
GKGilla Kaplan
Gilla Kaplan
STSteve Thomas
Steve Thomas
DFDaniel S. Fierer
Daniel S. Fierer
KMKathleen Mulligan
Kathleen Mulligan
PHPatrick A. J. Haslett
Patrick A. J. Haslett
MSMorris Schambelan
Morris Schambelan
A double-blind, placebo-controlled trial of efficacy and safety of thalidomide in AIDS-associated wasting was carried out. Ninety-nine of 103 male patients had at least one on-study measurement (intent-to-treat [ITT] cohort). Patients were randomized to thalidomide at 100 mg/day (T100) or 200 mg/day (T200), or placebo for 8 weeks. By ITT analysis, the mean change in body weight of the placebo, T100, and T200 treatment groups was 0.3 kg (0.4%), 2.0 kg (3.0%), and 0.9 kg (1.4%), respectively (p = 0.021 for T100 versus placebo; p = 0.53 for T200 versus placebo). Of the 64 patients who completed the 8 weeks of study treatment, significant weight gain was observed in both the T100 group (2.2 kg, [33%]; p = 0.008 versus placebo) and the T200 group (1.5 kg [2.5%]; p = 0.019 versus placebo). Approximately half the weight gain was fat-free mass (bioimpedance analysis). Patients in the T100 or T200 groups had no significant change in CD4+ cell counts, neutrophil counts, or TNF-alpha levels, compared with placebo. HIV viral load measured as log10 copies/ml decreased by a median of 0.07 in the placebo group, and increased by a median of 0.29 (T100 group) and 0.23 (T200 group) (p = 0.024 andp = 0.018 versus placebo, respectively). Thalidomide therapy was associated with mild to moderate rashes and fevers, but not peripheral neuropathy. Although the anabolic benefits of high-dose thalidomide are limited by drug intolerance, 8 weeks of low-dose thalidomide results in significant weight gain in patients with AIDS-associated wasting.

21 December 2012 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
DFDaniel S. Fierer
Daniel S. Fierer
DDDouglas T. Dieterich
Douglas T. Dieterich
MFM. Isabel Fiel
M. Isabel Fiel
ABAndrea D. Branch
Andrea D. Branch
KMKristen M. Marks
Kristen M. Marks
JFJoshua Fierer
Joshua Fierer
Background. We and others have shown that primary hepatitis C (HCV) infection in men infected with human immunodeficiency virus (HIV) causes early-onset liver fibrosis; however, little is known about the long-term natural history of the liver disease in these HIV-infected men. Methods. We followed a cohort of HIV-infected men with primary HCV infection in New York City. Results. Four men who were not cured after their primary HCV infection developed decompensated cirrhosis within 17 months to 6 years after primary HCV infection. Three died within 8 years of primary HCV infection, and 1 survived after liver transplant done 2 years after primary HCV infection. Three of the 4 men had AIDS at the time of primary HCV infection, and the most rapid progression occurred in the 2 men with the lowest CD4 counts at the time of HCV infection. Liver histopathology was most consistent with HCV-induced damage even though some had exposures to other potential hepatotoxins. Conclusions. Primary HCV infection resulted in decompensated cirrhosis and death within 2–8 years in 4 HIV-infected men. The rapid onset of fibrosis due to primary HCV infection in HIV-infected men cannot therefore be considered benign. The rate of continued progression to liver failure may be proportional to the degree of underlying immunocompromise caused by HIV infection. More research is needed to better define the mechanisms behind accelerated liver damage.